Nuvation Bio Inc. (NUVB) Spending and interest coverage
- R&D / revenue · 12 months: Value 75.84%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 20.90%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 75.84% | Research and development expense / revenue. Period ending 2026-06-30. $128.85M ÷ $169.90M × 100 ≈ 75.84% |
| Stock-based compensation / revenue · 12 months | 20.90% | Share-based compensation / revenue. Period ending 2026-06-30. $35.50M ÷ $169.90M × 100 ≈ 20.90% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 128.85M USD | Research and Development Expense |
| Revenue | 169.90M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 35.50M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -137.63M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $128.85M | $169.90M | $35.50M | $-137.63M | (m) | 75.84% | 20.90% | (m) | (m) |
| 2026-03-31 | $125.55M | $143.05M | $37.07M | $-150.18M | (m) | 87.77% | 25.92% | (m) | (m) |
| 2025-12-31 | $115.11M | $62.90M | $35.89M | $-213.06M | (m) | 182.99% | 57.06% | (m) | (m) |
| 2025-09-30 | $110.11M | $26.75M | $38.09M | $-232.97M | (m) | 411.65% | 142.42% | (m) | (m) |
| 2025-06-30 | $108.99M | $14.36M | $37.55M | $-224.64M | (m) | 759.27% | 261.58% | (m) | (m) |
| 2025-06-25 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $110.88M | $10.96M | $35.09M | $-631.43M | (m) | 1011.94% | 320.23% | (m) | (m) |
| 2024-12-31 | $99.12M | $7.87M | $32.27M | $-592.63M | (m) | 1258.97% | 409.95% | (m) | (m) |
| 2024-09-30 | $85.17M | (m) | $25.81M | $-559.52M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $76.00M | (m) | $23.76M | $-537.75M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $65.34M | (m) | $19.72M | $-93.50M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $71.29M | (m) | $19.51M | $-99.82M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $72.81M | (m) | $20.78M | $-103.33M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $75.54M | (m) | $18.29M | $-106.33M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $85.87M | (m) | $17.55M | $-118.06M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $87.81M | (m) | $16.29M | $-119.73M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $92.95M | (m) | $14.10M | $-125.01M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $88.77M | (m) | $13.91M | $-118.46M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $73.89M | (m) | $11.28M | $-101.03M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $69.04M | (m) | $9.27M | $-93.32M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | $-66.03M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | $-43.98M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |